J Burns1, S Ramchandren, M M Ryan, M Shy, R A Ouvrier. 1. Department of Neurology, Wayne State University-Detroit Medical Center, 4201 St. Antoine, UHC 8D, Detroit, MI 48201, USA.
Abstract
OBJECTIVE: We have shown that health-related quality of life (QOL) in children with inherited neuropathies (Charcot-Marie-Tooth disease [CMT]) is significantly reduced compared to population norms, thus establishing its utility as an outcome measure in therapeutic trials. However, the Australian ascorbic acid trial in children with CMT type 1A (CMT1A) identified no change in QOL scores despite a trend toward improvement in nerve conduction velocities in the treated group. The objective of this study was to identify clinical, electrophysiologic, and functional correlates of QOL in children with CMT1A, to guide future investigations of strategies to improve QOL and reduce disability in these patients. METHODS: In this cross-sectional study, a series of multivariate regression models were developed to determine whether QOL scores could be explained by demographic and symptom data, standardized measures of gross motor function, foot/ankle and hand/finger involvement, electrophysiology, and gait characteristics in 70 children aged 5-16 years with CMT1A. RESULTS: Independent determinants of reduced QOL in children with CMT1A, from strongest to weakest, were leg cramps, hand tremor, short step length, reduced long jump distance, ankle inflexibility, poor agility and endurance, advancing age, and foot drop. Many of the standardized clinical and electrophysiologic measures used as endpoints in clinical trials of CMT correlated poorly with QOL. CONCLUSION: QOL is negatively affected by CMT1A in children. Multivariate modeling suggests that interventions designed to improve leg cramps, tremor, agility, endurance, and ankle flexibility might have a substantial effect on QOL in children with CMT1A.
OBJECTIVE: We have shown that health-related quality of life (QOL) in children with inherited neuropathies (Charcot-Marie-Tooth disease [CMT]) is significantly reduced compared to population norms, thus establishing its utility as an outcome measure in therapeutic trials. However, the Australian ascorbic acid trial in children with CMT type 1A (CMT1A) identified no change in QOL scores despite a trend toward improvement in nerve conduction velocities in the treated group. The objective of this study was to identify clinical, electrophysiologic, and functional correlates of QOL in children with CMT1A, to guide future investigations of strategies to improve QOL and reduce disability in these patients. METHODS: In this cross-sectional study, a series of multivariate regression models were developed to determine whether QOL scores could be explained by demographic and symptom data, standardized measures of gross motor function, foot/ankle and hand/finger involvement, electrophysiology, and gait characteristics in 70 children aged 5-16 years with CMT1A. RESULTS: Independent determinants of reduced QOL in children with CMT1A, from strongest to weakest, were leg cramps, hand tremor, short step length, reduced long jump distance, ankle inflexibility, poor agility and endurance, advancing age, and foot drop. Many of the standardized clinical and electrophysiologic measures used as endpoints in clinical trials of CMT correlated poorly with QOL. CONCLUSION: QOL is negatively affected by CMT1A in children. Multivariate modeling suggests that interventions designed to improve leg cramps, tremor, agility, endurance, and ankle flexibility might have a substantial effect on QOL in children with CMT1A.
Authors: B W Stansfield; S J Hillman; M E Hazlewood; A M Lawson; A M Mann; I R Loudon; J E Robb Journal: Gait Posture Date: 2003-02 Impact factor: 2.840
Authors: K M Krajewski; R A Lewis; D R Fuerst; C Turansky; S R Hinderer; J Garbern; J Kamholz; M E Shy Journal: Brain Date: 2000-07 Impact factor: 13.501
Authors: J B Lane; H-S Lee; L W Smith; P Cheng; A K Percy; D G Glaze; J L Neul; K J Motil; J O Barrish; S A Skinner; F Annese; L McNair; J Graham; O Khwaja; K Barnes; J P Krischer Journal: Neurology Date: 2011-10-19 Impact factor: 9.910
Authors: Maria Nolano; Fiore Manganelli; Vincenzo Provitera; Chiara Pisciotta; Annamaria Stancanelli; Giuseppe Caporaso; Rosa Iodice; Michael E Shy; Lucio Santoro Journal: Neurology Date: 2014-12-24 Impact factor: 9.910
Authors: Nicholas E Johnson; Janet Sowden; Nuran Dilek; Katy Eichinger; Joshua Burns; Michael P Mcdermott; Michael E Shy; David N Herrmann Journal: Muscle Nerve Date: 2015-02-11 Impact factor: 3.217
Authors: Nicholas E Johnson; Chad R Heatwole; Nuran Dilek; Janet Sowden; Callyn A Kirk; Denise Shereff; Michael E Shy; David N Herrmann Journal: Neuromuscul Disord Date: 2014-06-27 Impact factor: 4.296
Authors: Nicholas E Johnson; Chad R Heatwole; Michele Ferguson; Janet E Sowden; Shanie Jeanat; David N Herrmann Journal: J Clin Neuromuscul Dis Date: 2013-09